Literature DB >> 10514477

Mutants of interleukin 13 with altered reactivity toward interleukin 13 receptors.

J P Thompson1, W Debinski.   

Abstract

Interleukin 13 (IL13) belongs to a family of cytokines whose members exhibit structural homology, despite amino acid sequence dissimilarity. For example, while of limited sequence homology, IL13 and IL4 share a signaling receptor, IL13/4 receptor, on a variety of human normal cells. However, a subclass of IL4-independent IL13 receptors is overexpressed on certain transformed cells, including human malignant gliomas. We introduced mutations into human (h) IL13 to determine the site(s) involved in interaction with the shared receptor and/or the glioma-associated receptor. This analysis identified at least three protein regions that are needed for signaling through the shared receptor. These regions were localized to alpha-helices A, C, and D and were mainly separate from the region(s) needed to interact with the glioma-associated receptor. Glutamic acids at positions 13 and 16 in hIL13 alpha-helix A, arginine and serine at positions 66 and 69 in helix C, and arginine at position 109 in helix D were found to be important in inducing biological signaling since their specific mutation resulted in loss and/or gain of function phenomena. We demonstrate that the molecular requirements of hIL13 to interact with its respective receptors are generally distinct and can be controlled by mutagenesis of the cytokine.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10514477     DOI: 10.1074/jbc.274.42.29944

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

1.  When better still might not be good enough.

Authors:  Waldemar Debinski
Journal:  Transl Cancer Res       Date:  2017-10       Impact factor: 1.241

2.  An interleukin 13 receptor α 2-specific peptide homes to human Glioblastoma multiforme xenografts.

Authors:  Hetal Pandya; Denise M Gibo; Shivank Garg; Steven Kridel; Waldemar Debinski
Journal:  Neuro Oncol       Date:  2011-09-26       Impact factor: 12.300

3.  T cells redirected to interleukin-13Rα2 with interleukin-13 mutein--chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1.

Authors:  Simone Krebs; Kevin K H Chow; Zhongzhen Yi; Tania Rodriguez-Cruz; Meenakshi Hegde; Claudia Gerken; Nabil Ahmed; Stephen Gottschalk
Journal:  Cytotherapy       Date:  2014-05-16       Impact factor: 5.414

4.  Novel Molecular Multilevel Targeted Antitumor Agents.

Authors:  Poonam Sonawane; Young A Choi; Hetal Pandya; Denise M Herpai; Izabela Fokt; Waldemar Priebe; Waldemar Debinski
Journal:  Cancer Transl Med       Date:  2017-06-08

5.  Molecular targeting of intracellular compartments specifically in cancer cells.

Authors:  Hetal Pandya; Denise M Gibo; Waldemar Debinski
Journal:  Genes Cancer       Date:  2010-05

6.  Interleukin 13 mutants of enhanced avidity toward the glioma-associated receptor, IL13Ralpha2.

Authors:  A B Madhankumar; Akiva Mintz; Waldemar Debinski
Journal:  Neoplasia       Date:  2004 Jan-Feb       Impact factor: 5.715

7.  Reoxygenation of hypoxic glioblastoma multiforme cells potentiates the killing effect of an interleukin-13-based cytotoxin.

Authors:  Tie Fu Liu; Jiaozhong Cai; Denise M Gibo; Waldemar Debinski
Journal:  Clin Cancer Res       Date:  2009-01-01       Impact factor: 12.531

8.  Molecular targeting with recombinant cytotoxins of interleukin-13 receptor alpha2-expressing glioma.

Authors:  Akiva Mintz; Denise M Gibo; A B Madhankumar; Waldemar Debinski
Journal:  J Neurooncol       Date:  2003 Aug-Sep       Impact factor: 4.130

9.  A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker.

Authors:  Van Nguyen; Jesse M Conyers; Dongqin Zhu; Denise M Gibo; Roy R Hantgan; Steven M Larson; Waldemar Debinski; Akiva Mintz
Journal:  Neuro Oncol       Date:  2012-09-05       Impact factor: 12.300

10.  IL-13Ralpha2 is a glioma-restricted receptor for interleukin-13.

Authors:  Akiva Mintz; Denise M Gibo; Becky Slagle-Webb; Neil D Christensen; Waldemar Debinski
Journal:  Neoplasia       Date:  2002 Sep-Oct       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.